Issue: For five years now, public concern about genetic engineering has been riveted on GM crops and foods. But, advances in mapping the human genome have spawned new pharmaceutical industry opportunities. While the prospects for human cloning and stem cell therapies grab the headlines and divert our attention, the companies are pursuing more strategic agendas. Although the majority oppose reproductive cloning, public and policy opinion is 'soft.' Industry's latest and most lucrative market - Human Performance Enhancement drugs - 'HyPEs' - are not even on the policy agenda. This issue of ETC Group Communique looks at the latest developments as well as who is going to be most affected.